Novo Nordisk (NVO) starts DKK 3.8B early-2026 share repurchase
Rhea-AI Filing Summary
Novo Nordisk A/S is launching its 2026 share repurchase programme of up to DKK 15 billion. As part of this, it has started a new buyback of up to DKK 3.8 billion to run from 4 February 2026 through 4 May 2026.
The company states the purpose is to reduce its share capital and meet obligations from share-based incentive programmes, with a maximum of 400,000,000 B shares of DKK 0.10 in total that can be purchased during the trading period. The programme relies on an existing repurchase authorisation granted at the 27 March 2025 Annual General Meeting and its continuation beyond 26 March 2026 will depend on renewed approval at the 2026 meeting.
The buyback will follow EU Market Abuse Regulation Article 5 and related Safe Harbour Rules, with Nordea Danmark acting as lead manager.
Positive
- None.
Negative
- None.
Insights
Novo Nordisk sets a sizeable 2026 buyback under EU safe harbour rules.
Novo Nordisk plans an overall 2026 share repurchase of up to DKK 15 billion, starting with a new programme of up to DKK 3.8 billion running from 4 February 2026 to 4 May 2026. The stated goals are share capital reduction and servicing share-based incentives.
The company can purchase up to 400,000,000 B shares of DKK 0.10 in total during this trading period under an authorisation granted at the 27 March 2025 Annual General Meeting. Any continuation beyond 26 March 2026 will depend on renewed AGM approval, so the scale after that point depends on shareholder decisions.
The programme will be executed under Article 5 of MAR and the EU Safe Harbour Rules, with Nordea Danmark as lead manager, which frames the buybacks within well-defined trading and disclosure mechanics. Subsequent announcements during the period may detail actual repurchase volumes and prices.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
How large is Novo Nordisk’s new 2026 buyback tranche and when does it run?
Under which regulations will Novo Nordisk’s 2026 buyback be conducted?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
February 4, 2026
________________
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
Novo Allé 1
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
| Form 20-F ☒ | Form 40-F ☐ |
Novo Nordisk initiates 2026 share repurchase programme
Bagsværd, Denmark, 4 February 2026 –The execution of Novo Nordisk A/S' overall share repurchase programme for 2026 of up to DKK 15 billion will be initiated on 4 February 2026. As part of this, Novo Nordisk A/S today initiates a new share repurchase programme for an amount up to DKK 3.8 billion, to be executed during the trading period 4 February 2026 through 4 May 2026. The purpose of the programme is to reduce the company's share capital and to meet obligations arising from share-based incentive programmes. A maximum of 400,000,000 B shares of DKK 0.10 in total can be bought during the trading period.
At the Annual General Meeting on 27 March 2025, an authorisation valid until the Annual General Meeting in 2026 allowing the Company to repurchase own shares was granted. Continuation of the share repurchase programme beyond 26 March 2026 is conditional upon an authorisation to repurchase own shares being granted at the Annual General Meeting 2026.
The programme will be conducted in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules”).
Nordea Danmark, Filial af Nordea Bank Abp, Finland, will be acting as lead manager on the programme.
Page 2 of 2
About Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
| Media: | |
| Ambre James-Brown | Liz Skrbkova (US) |
| +45 3079 9289 | +1 609 917 0632 |
| globalmedia@novonordisk.com | lzsk@novonordisk.com |
| Investors: | |
| Michael Novod | Jacob Martin Wiborg Rode |
| +45 3075 6050 | +45 3075 5956 |
| nvno@novonordisk.com | jrde@novonordisk.com |
| Max Ung | Sina Meyer |
| +45 3077 6414 | +45 3079 6656 |
| mxun@novonordisk.com | azey@novonordisk.com |
| Alex Bruce | Christoffer Sho Togo Tullin |
| +45 34 44 26 13 | +45 3079 1471 |
| axeu@novonordisk.com | cftu@novonordisk.com |
| Frederik Taylor Pitter | |
| +1 609 613 0568 | |
| fptr@novonordisk.com |
Novo Nordisk A/S Investor Relations | Novo Allé 1 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | Internet: |
| Company announcement No 06 / 2026 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
| Date: February 4, 2026 |
NOVO NORDISK A/S
Maziar Mike Doustdar Chief Executive Officer |